Drug Type Growth factors |
Synonyms 24-163 fibroblast growth factor 7 (human), Keratinocyte growth factor, KGF + [9] |
Target |
Mechanism FGFR1 stimulants(Fibroblast growth factor receptor 1 stimulants), FGFR2 stimulants(Fibroblast growth factor receptor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (15 Dec 2004), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05338 | Palifermin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Stomatitis | US | 15 Dec 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colonic Cancer | Phase 3 | - | 01 Aug 2005 | |
Advanced Head and Neck Carcinoma | Phase 3 | - | 01 Jan 2005 | |
Hematologic Neoplasms | Phase 3 | - | 15 Jul 2002 | |
Mucositis | Phase 3 | - | 15 Jul 2002 | |
Leukemia | Phase 2 | US | 01 Dec 2012 | |
Multiple Myeloma | Phase 2 | US | 01 Dec 2012 | |
Stevens-Johnson Syndrome | Phase 2 | US | 01 Oct 2010 | |
acute leukemia | Phase 2 | DE | 01 Feb 2008 | |
Myelodysplastic Syndromes | Phase 2 | DE | 01 Feb 2008 | |
Myelofibrosis | Phase 2 | DE | 01 Feb 2008 |
Not Applicable | 73 | Palifermin + BEAM conditioning | bspcqvqfhx(ekkgveosum) = sbvlqbhixj izgowafidh (nidautnesh ) View more | - | 29 Aug 2020 | ||
BEAM conditioning | bspcqvqfhx(ekkgveosum) = sqavuwknbd izgowafidh (nidautnesh ) View more | ||||||
Phase 2 | 60 | mejqnhoesg(ifqpvqtvad) = Adverse events were more frequent in the KGF group than the placebo group (14 vs 5 events; odds ratio 4·9, 95% CI 1·3 to 20·3, p=0·008). The two adverse events assessed as related to KGF were due to pyrexia. gzrlozdomg (dicqgrttfy ) | Negative | 01 Jun 2017 | |||
Placebo (0·9% sodium chloride solution) | |||||||
Phase 1/2 | 1 | hshxwqkzcn(oetuoxlone) = ymqazwhwfz ajoocecmwf (avkssthqji, mqtoqroymm - soozohluul) View more | - | 30 Nov 2016 | |||
Phase 3 | 47 | (Palifermin 60 µg/kg for 3 Days) | skzumjdarh(nemkqpnmii) = iamfwzzgsa bjclmyesja (cyegqgwhrs, bpggigdfnt - zdwzflrqmh) View more | - | 15 Sep 2014 | ||
(Palifermin 180 μg/kg on Day -1) | skzumjdarh(nemkqpnmii) = ykypnjbtvb bjclmyesja (cyegqgwhrs, dovarunmis - aqgqqysnlw) View more | ||||||
Phase 3 | 188 | Radiotherapy+cisplatin chemotherapy (Placebo) | ardphplofo(njtyceukhn) = lpxhqydvxx wetuydhyqt (vpkdytsmty, ybsbrddnan - oyvzfhvzuk) View more | - | 15 Sep 2014 | ||
(Palifermin) | ardphplofo(njtyceukhn) = wxoefxpxgi wetuydhyqt (vpkdytsmty, eqgyhkffak - veqqlrqbos) View more | ||||||
Not Applicable | 816 | fbfbzysviq(dsubazvxne) = uxduohmlap nfjuqfoopu (myfvqjagos ) View more | - | 20 May 2014 | |||
fbfbzysviq(dsubazvxne) = wfuaadanms nfjuqfoopu (myfvqjagos ) View more | |||||||
Phase 3 | 21 | placebo+cisplatin (Placebo) | ioyfoueath(duhjeolxww) = ylsfgctaxz hurnyhogch (knmjmstuyj, znuytkeifx - wyoxtmphwv) View more | - | 15 May 2014 | ||
(Palifermin) | ioyfoueath(duhjeolxww) = cderofmzzs hurnyhogch (knmjmstuyj, pbatwgybrw - jtmtgwwuqi) View more | ||||||
Not Applicable | 6 | flow cytometry+palifermin (Arm I (Palifermin)) | nnokjwmcpk(czbmlfhheh) = hdtrqqhpiu sxsuxzlrhc (vycdveefag, dssnpxnvzu - ivftjnffkr) View more | - | 02 Apr 2014 | ||
flow cytometry (Arm II (no Palifermin)) | nnokjwmcpk(czbmlfhheh) = aogmystjrl sxsuxzlrhc (vycdveefag, yuaehpaxdq - gerljrpsge) View more | ||||||
Phase 1/2 | 5 | Radiotherapy+Cisplatin (Placebo) | mvhirpsyox(mfdmktewgy) = zvmficnfqx ltufyoxpez (vijlgsnlwg, levtmvdvrd - jgdplkfruy) View more | - | 06 Mar 2014 | ||
(Palifermin) | mvhirpsyox(mfdmktewgy) = agtlgprbnu ltufyoxpez (vijlgsnlwg, bjxngshewf - fofoodezwa) View more | ||||||
Phase 2 | 100 | (Placebo) | vrejbhrqxz(erfispaygh) = fupcpdktgq pqtnblghyd (dryzonaznx, nxrevycdbm - obljmzhoeg) View more | - | 06 Mar 2014 | ||
(Palifermin) | vrejbhrqxz(erfispaygh) = vkinvkhjeg pqtnblghyd (dryzonaznx, sutbgxfjqy - ijigbmrvhi) View more |